Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Am J Cardiol. 2019 Dec 10;125(5):727–734. doi: 10.1016/j.amjcard.2019.12.006

Figure 3.

Figure 3.

Meta-analysis for cardiovascular mortality. Individual and summary hazard ratios for myocardial infarction. 4S (SSSS) = Scandinavian Simvastatin Survival Study; ALLHAT-LLT = AFCAPS-TexCAPS, Air Force/Texas Coronary Atherosclerosis Prevention Study; ALERT = Assessment of LEscol in Renal Transplantation Study; ASCOT-LLA = Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm; ASPEN = Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus; CARE = Cholesterol And Recurrent Events; CARDS = Collaborative Atorvastatin Diabetes Study; FOURIER = Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk; GISSI-P = Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico; HOPE-3 = Heart Outcomes Prevention Evaluation; GREACE = The GREek Atorvastatin and Coronary-heart-disease Evaluation Study; HPS = Heart Protection Study; IDEAL = Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group; IMPROVE-IT = Improved Reduction of Outcomes: Vytorin Efficacy International Trial; JUPITER = Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin study group; LIPID = Long-term Intervention with Pravastatin in Ischaemic Disease; MEGA = Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese Study Group; ODYSSEY LONG TERM = Long-term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy; ODYSSEY Outcomes = Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; PROVE IT-TIMI 22 = the Pravastatin or Atorvastatin Evaluation and Infection Therapy; PROSPER = PROspective Study of Pravastatin in the Elderly at Risk; SEARCH = Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine; SEAS = Simvastatin and Ezetimibe in Aortic Stenosis; SHARP = Study of Heart and Renal Protection; SPARCL = The Stroke Prevention by Aggressive Reduction in Cholesterol Levels; SPIRE 1 & 2 = Studies of PCSK9 Inhibition and the Reduction of Vascular Events 1 & 2; TNT - Treating to New Targets; WOSCOPS = West of Scotland Coronary Prevention Study.